Wednesday, May 25, 2022 10:30:10 AM
The written responses, and the responses provided in a teleconference with FDA representatives, were constructive and supportive, with interest in the project underpinned by the significant cohort of people diagnosed with OSA and the absence of pharmacological treatment solutions.
FDA provided guidance on Incannex's proposed long-term development strategy, including specific parameters to demonstrate safety and efficacy in phase 2 and 3 pivotal studies. Guidance provided by the FDA to the Company will inform adjustments to the clinical trial protocols to ensure that they generate the data required for a 505(b)(2) new drug application (NDA).
In a decision that will save Incannex time and cost, FDA agreed that Incannex does not need to conduct studies in animals. In particular, the agency confirmed that animal toxicology and animal pharmacokinetic (PK) studies are not required for opening an IND for IHL-42X. Therefore, the next step for the development of IHL-42X will be the adjustment of clinical trial designs and arrangement of operational imperatives necessary to open an IND with FDA.
https://finance.yahoo.com/news/incannex-announces-positive-pre-ind-115500713.html
Recent IXHL News
- Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder • GlobeNewswire Inc. • 05/07/2024 11:30:00 AM
- Incannex Healthcare Inc. Quarterly Update, Q1 2024 • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder • GlobeNewswire Inc. • 02/28/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 01:00:11 PM
- Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation • GlobeNewswire Inc. • 02/16/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 11:16:51 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 12:30:16 PM
- Clarion Clinics Open for Psychedelic-Assisted Treatments • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:30:18 PM
- Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis • GlobeNewswire Inc. • 01/24/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 02:08:33 PM
- Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences • GlobeNewswire Inc. • 01/18/2024 01:22:34 PM
- Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea • GlobeNewswire Inc. • 01/17/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 11:05:45 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 11:07:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 01:54:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 01:53:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 01:50:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/22/2023 01:47:51 AM
- Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia • GlobeNewswire Inc. • 12/21/2023 09:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/20/2023 10:05:54 PM
- Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea • GlobeNewswire Inc. • 12/06/2023 12:30:00 PM
- Incannex Healthcare Announces Completion of its Redomiciliation to the United States • GlobeNewswire Inc. • 11/29/2023 06:40:29 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/16/2023 02:38:31 PM
- Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC • GlobeNewswire Inc. • 11/16/2023 01:30:00 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM